Bioness Medical today announced the acquisition of the PoNS (Portable Neuromodulation Stimulator) System product line.
The addition of the PoNS System expands the company's platform to include non-invasive neuromodulation delivered via the tongue, stimulating cranial nerve pathways to promote neuroplasticity and functional recovery.
The PoNS System has been studied in patients with chronic neurological conditions, demonstrating improvements in gait and balance when used as part of a supervised rehabilitation program.
The acquisition brings together complementary technology platforms:
- Bioness Medical's portfolio, including L300 Go, H200 Wireless, and Vector Gait & Safety System
- PoNS neuromodulation therapy, designed to promote neuroplasticity through non-invasive cranial nerve stimulation via the tongue
Together, these technologies enable clinicians to address both peripheral motor activation and central neural network modulation within a unified rehabilitation approach.
The acquisition also enhances Bioness Medical's research and development capabilities and supports expanded clinical programs, including combination therapy approaches integrating FES and neuromodulation.
